- Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall®, are the most commonly abused preparation of prescription stimulants
- Company’s abuse-deterrent stimulant formulations have the potential to address misuse and abuse of stimulant medication by non-oral routes, such as snorting
- Pivotal abuse study of the Company’s lead investigational program
The poster titled, “Characteristics and Behaviors of Recreational Prescription Stimulant Users: Findings from an mTurk online survey,” outlined additional results from a large survey, led by researchers at the
The survey was conducted through a common online platform, MTurk, which has been used in addiction science research to efficiently crowd source information from large populations.
“Among the more interesting findings of the survey were reports that people who snort prescription stimulants typically spend less than 10 minutes to prepare a stimulant for snorting, and if they were unable to manipulate a stimulant for snorting, very few claim they would escalate to a more serious route of abuse such as injecting or take a more harmful drug instead,” stated
Summary of Results
- A total of 496 responders who were surveyed reported using a prescription stimulant when not prescribed; >150 admitted snorting prescription stimulants.
- While most abusers reported taking prescription stimulants orally, 32% reported snorting, 2% injecting, and 4% vaping.
- Prescription stimulant snorters were more likely than overall abusers to also report using other controlled substances including cannabis, cocaine, opioids, and methamphetamine.
- Almost 90% of prescription stimulant snorters have done so with an IR amphetamine.
- Adderall (mixed amphetamine salts immediate release) was the most commonly snorted prescription stimulant (n=135).
- More than 40% of respondents who snorted Adderall say their typical dose is up to 10 mg, 40% say 11–30 mg, and <5% report doses >30 mg.
- Over 80% of those who snort say it takes no more than 5 minutes to manipulate; over 90% say it takes no more than 10 minutes.
- Over 90% of snorters say they would take prescription stimulants orally if unable to manipulate for snorting; <5% would try to prepare prescription stimulants to inject.
The APSARD poster presentation can be accessed on the Publications page of the Company’s website.
About
For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.
Forward Looking Statements
This press release contains “forward-looking statements” that are based on Vallon’s current expectations and subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation, Vallon’s ability to execute its business plan, continue its growth and fund its ongoing business activities as planned, Vallon’s ability to develop and commercialize its product candidates, expectations related to results of clinical trials and studies, Vallon’s expectations with respect to the important advantages it believes its abuse-deterrent formulation of drugs have over similar drugs in the market and the growing need for abuse-deterrent formulations of drugs, Vallon’s ability to utilize the 505(b)(2) regulatory pathway, Vallon’s ability to obtain FDA approval of
Investor Contact:
(833) 475-8247
vallon@jtcir.com
![](https://ml.globenewswire.com/media/YTQzZDBiOGUtZDMwYi00YmU0LTg5MjMtMmU0NzFkMjhkYTdhLTUwMDA3NTQ4OA==/tiny/Vallon-Pharmaceuticals-Inc-.png)
2022 GlobeNewswire, Inc., source